Glenmark Pharmaceuticals Limited provided earnings guidance for the fiscal year 2025. The consolidated revenue target is INR 135,000 million to INR 140,000 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,220 INR | -0.87% | -1.85% | +42.85% |
06-12 | India Equities Close Higher Ahead of US Inflation Data | MT |
06-12 | Glenmark Pharmaceuticals Gets US FDA Final Nod for Esomeprazole Magnesium Capsules | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+42.85% | 4.15B | |
+18.66% | 42.12B | |
+23.31% | 21.72B | |
+20.71% | 14.89B | |
+56.75% | 13.06B | |
-0.05% | 6.79B | |
-12.68% | 6.3B | |
+20.03% | 6.05B | |
-8.87% | 5.73B | |
+6.29% | 4.58B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Glenmark Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2025